Down -20.26% in 4 Weeks, Here's Why LifeStance Health (LFST) Looks Ripe for a Turnaround
LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LifeStance Health Group (LFST) Reports Break-Even Earnings for Q1
LifeStance Health Group (LFST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago.
Wall Street Analysts Believe LifeStance Health (LFST) Could Rally 28.68%: Here's is How to Trade
The mean of analysts' price targets for LifeStance Health (LFST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LifeStance Health Group: Solid Execution Drives Growth And Margin Expansion
I remain bullish on LifeStance Health Group stock due to robust demand, clinician retention, and margin expansion potential, despite recent share price declines. LFST's flexible hybrid care model and digital check-in tool enhance clinician retention and patient accessibility, driving sustainable growth and competitive advantage. LFST's adjusted EBITDA margin reached 10.1% in 4Q24, with management targeting 15-20% over time, supported by operational efficiencies and higher-margin services.
LifeStance Health (LFST) Surges 5.8%: Is This an Indication of Further Gains?
LifeStance Health (LFST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
LifeStance Health (LFST) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LifeStance Health Group, Inc. (LFST) Q4 2024 Earnings Call Transcript
LifeStance Health Group, Inc. (NASDAQ:LFST ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Monica Prokocki - VP, IR Ken Burdick - CEO David Bourdon - CFO Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Jamie Perse - Goldman Sachs Brian Tanquilut - Jefferies Andrea Alfonso - UBS Operator Thank you for standing by. My name is Danielle, and I will be your conference operator today.
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago.
LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LifeStance Health (LFST) Upgraded to Strong Buy: Here's What You Should Know
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LifeStance upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded LifeStance to Buy from Neutral with a $10 price target. Amid rising policy uncertainty, with a wide range of potential outcomes, Goldman is taking a more cautious view on healthcare providers, the analyst tells investors in a research note. With this view, the firm downgraded hospitals Tenet (THC) and Universal Health (UHS) to Neutral while upgrading Lifestance Health Group (LFST) to Buy, where it believes the company is more insulated from policy risk. The analyst believes LifeStance's continued operational execution will continue in 2025, and on an organic basis, Goldman's analysis suggests its EBITDA can grow 27% through 2027.
